Skip to content

Comparison of clinical efficacy between autologous partially demineralized dentin matrix and deproteinized bovine bone mineral for bone augmentation in orthodontic patients with alveolar bone deficiency: a randomized controlled clinical trial

Comparison of clinical efficacy between autologous partially demineralized dentin matrix and deproteinized bovine bone mineral for bone augmentation in orthodontic patients with alveolar bone deficiency: a randomized controlled clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400084607
Enrollment
Unknown
Registered
2024-05-21
Start date
2020-07-01
Completion date
Unknown
Last updated
2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

alveolar bone deficiency

Interventions

experimental group:APDDM was implanted in the area of the alveolar bone defect.
control group:DBBM was implanted in the area of the alveolar bone defect.

Sponsors

The Stomatology Hospital of Zhejiang Chinese Medicine University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
19 Years to 43 Years

Inclusion criteria

Inclusion criteria: 1. Individuals without a history of uncontrollable systemic diseases. 2. Orthodontic patients with insufficient alveolar bone diagnosed by CBCT in the targeted area of tooth movement. 3. Stable periodontal condition, having completed comprehensive basic periodontal treatment at least 4 weeks prior. 4. Excellent oral hygiene and compliance. 5. No use of medications that affect bone metabolism in the past six months.

Exclusion criteria

Exclusion criteria: 1. Individuals with severe systemic diseases that preclude surgical tolerance. 2. Individuals with severe psychological or psychiatric disorders. 3. Patients with significant smoking or alcohol use and other detrimental habits that cannot be ceased. 4. Patients who are pregnant or breastfeeding. 5. Individuals with acute infections in the affected tooth or adjacent teeth. 6. Individuals suffering from osteoarthritic diseases on long-term bisphosphonate therapy. 7. Individuals with hyperthyroidism, diabetes, and other systemic conditions that impact bone metabolism. 8. Patients who have undergone previous bone grafting at the surgical site.

Design outcomes

Primary

MeasureTime frame
buccal alveolar heights;central alveolar heights;widths at the alveolar ridge apex;widths at 3 mm below the alveolar ridge apex;widths at 5 mm below the alveolar ridge apex;

Secondary

MeasureTime frame
Postoperative response;

Countries

China

Contacts

Public ContactShuhua Wang

School of Stomatology, Zhejiang Chinese Medical University

wangshuhua101@163.com+86 135 8883 5981

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 6, 2026